article thumbnail

STAT+: Drug shortages reached a record high as 2023 drew to a close

STAT

stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. The number of ongoing and active drug shortages in the U.S.

article thumbnail

STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more

STAT

stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country, STAT tells us. Unresolved The number of ongoing and active drug shortages in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT Antibody, ISB 2001

Express Pharma

No immune cell-associated neurotoxicity syndrome (ICANS) was observed. This innovative design can increase binding to tumour cells while minimising on-target, off-tumour side effects and/or boost immune cell activity against tumour cells by triggering multiple signals. The median duration of CRS was 2 days (range: 18).

article thumbnail

What Can One Life Tell Us About the Battle Against H.I.V.?

NY Times

In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. That preceded an ambitious global campaign to curb the virus. How well did it work?

article thumbnail

GSK enters agreement with Canada for influenza vaccines

Pharmaceutical Technology

The latest contract comes after previous agreements between the parties for seasonal influenza and pandemic vaccines dating back to 2001. Arepanrix includes a monovalent, inactivated influenza virus antigen strain as well as the pandemic adjuvant system of GSK.

article thumbnail

Using alkali-metal cation recognition of ?-cyclodextrin to detect lithium ions by MALDI-TOF

European Pharmaceutical Review

Following post-doctoral studies on proteomics at Purdue University, under supervision of Professor Fred E Regnier, Ahmad joined the SMPA laboratory in 2001. Johan’s PhD studies at the University of Gothenburg were focused on food and allergy, and the effect of fatty acids on immune cells. Schalley CA. Lee JU, Lee SS, Lee S, et al.,

article thumbnail

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

pharmaphorum

Most CRISPR therapies clinical trials so far have taken the ex vivo approach, but a number of in vivo therapies have now started testing in humans, including Editas’ EDIT-101 for LCA10, a rare form of blindness, and Intellia/Regeneron’s NTLA-2001 transthyretin amyloidosis.